Data / New clinical trials / Esophageal Squamous Cell Carcinoma

Esophageal Squamous Cell Carcinoma trials: 143 new

Name: New Esophageal Squamous Cell Carcinoma clinical trials
Creator: SpecStream
License: https://creativecommons.org/licenses/by/4.0/

The full list. New Esophageal Squamous Cell Carcinoma clinical trials: 143 rows for $7.15, first posted on ClinicalTrials.gov from November 12, 2024 to November 9, 2026. The list gains about 5 rows a month. The new rows come each week by email, $19 a month.

Get this list free

$10 of credit on sign-up, no card. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (central contact, contact phone, contact email, sponsor class, condition groups (MeSH), interventions and 5 more), which open on your screen as soon as the payment clears and come by email. The weekly rows run until you cancel, from the link in each delivery. To get the new rows in your own tools, use SpecStream on Zapier. The rows on this page are a sample.

For agents and scripts: this list is ordered at https://specstream.ai/data/clinical-trials/condition/esophageal-squamous-cell-carcinoma, and every list with its row count and price is at https://specstream.ai/data/lists.json.

Updated November 9, 2026. Source: ClinicalTrials.gov API v2 (U.S. National Library of Medicine).

143 clinical studies in Esophageal Squamous Cell Carcinoma were first posted on ClinicalTrials.gov from November 12, 2024 to November 9, 2026; 29 have an industry sponsor and 110 are recruiting or about to. The newest, NCT07924111, was posted on November 9, 2026: A Randomized, Controlled, Double-Blind, Multicenter Phase III Clinical Trial to Evaluate the Efficacy and... (CSPC Megalith Biopharmaceutical Co.,Ltd.).

The request: Every new Esophageal Squamous Cell Carcinoma clinical trial on ClinicalTrials.gov, with the sponsor, phase, sites and the listed contact.

Get new trials like these Watch a sponsor

SpecStream is the live web data engine for teams and agents. It reads every new study on ClinicalTrials.gov each morning, and this page is that reading. Ask for the conditions, phases or countries you follow and each new trial arrives in your sheet, CRM, Slack or agent with the sponsor, the sites and the listed contact.

143New trials
29Industry sponsored
110Recruiting or not yet
November 9, 2026Latest posted

Newest trials

The newest 100 of 143, each linked to its record. The full list holds every one with the sponsor class, interventions, start date and the central contact as the record prints it.

First posted	NCT ID	Title	Sponsor	Phase	Status	Conditions	Enrollment	Countries	Source
November 9, 2026	NCT07924111	A Randomized, Controlled, Double-Blind, Multicenter Phase III Clinical Trial to Evaluate the Efficacy and Safety of Enlonstobart, With or...	CSPC Megalith Biopharmaceutical Co.,Ltd.	Phase 3	Not yet recruiting	Esophageal Squamous Cell Carcinoma	585		clinicaltrials.gov
November 2, 2026	NCT07909031	CR-002 in Adult Participants With Locally Advanced or Metastatic Solid Tumors	Crescent Biopharma, Inc.	Phase 1/2	Recruiting	Head and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic (R/M), Gastric/GEJ, Biliary Tract Cancer (BTC)...	219	United States	clinicaltrials.gov
October 29, 2026	NCT07902544	Station-Specific Lymph Node Metastasis After Neoadjuvant Chemoimmunotherapy for Middle Thoracic Esophageal Squamous Cell Carcinoma	Daping Hospital and the Research Institute of Surgery of the Third Military Medical University	Observational	Completed	Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms, Metastasis	717		clinicaltrials.gov
October 19, 2026	NCT07879898	Radiotherapy Target Volume in Locally Advanced Esophageal Squamous Cell Carcinoma in the Immunotherapy Era	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	Observational	Active not recruiting	Esophageal Squamous Cell Carcinoma	500	China	clinicaltrials.gov
October 5, 2026	NCT07858630	Radiotherapy Target Volume Delineation in Locally Advanced Esophageal Cancer in the Immunotherapy Era	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	Observational	Recruiting	Esophageal Squamous Cell Carcinoma	500	China	clinicaltrials.gov
September 23, 2026	NCT07836049	PhII Study of Toripalimab Followed by Definitive CRT & Adjuvant Toripalimab in Locally Advanced ESCC	Vanderbilt-Ingram Cancer Center	Phase 2	Not yet recruiting	Esophageal Squamous Cell Carcinoma	20	United States	clinicaltrials.gov
September 21, 2026	NCT07830355	Immunotherapy Plus Anlotinib After Surgery for Esophageal Squamous Cell Cancer With Residual Tumor and Positive Lymph Nodes	Shanghai Chest Hospital	Phase 2	Not yet recruiting	Esophageal Squamous Cell Carcinoma	75		clinicaltrials.gov
September 16, 2026	NCT07823270	Neoadjuvant Sacituzumab Tirumotecan Plus Toripalimab in Locally Advanced Esophageal Squamous Cell Carcinoma	Hebei Medical University Fourth Hospital	Phase 2	Not yet recruiting	Esophageal Squamous Cell Carcinoma	33	China	clinicaltrials.gov
September 16, 2026	NCT07822906	Risk of Esophageal Cancer Returning After Immunotherapy, Chemotherapy, and Surgery	Peking University Cancer Hospital & Institute	Observational	Not yet recruiting	Esophageal Squamous Cell Carcinoma (ESCC)	100	China	clinicaltrials.gov
September 10, 2026	NCT07811752	Sacituzumab Govitecan Combined With Tislelizumab for Locally Advanced/Metastatic Esophageal Cancer	Shanghai Chest Hospital	Phase 2	Recruiting	Esophageal Squamous Cell Carcinoma	28	China	clinicaltrials.gov
September 2, 2026	NCT07799077	Paclitaxel Polymeric Micelles and Cisplatin Plus Sintilimab as Neoadjuvant Therapy for Resectable Locally Advanced Esophageal Squamous Cell...	Hebei Medical University Fourth Hospital	Phase 2	Not yet recruiting	Esophageal Squamous Cell Carcinoma	32	China	clinicaltrials.gov
August 31, 2026	NCT07796113	Adebrelimab With Famitinib and Chemotherapy as Neoadjuvant Therapy for ESCC	First Affiliated Hospital Xi'an Jiaotong University	Phase 2	Recruiting	Esophageal Squamous Cell Carcinoma	24	China	clinicaltrials.gov
August 21, 2026	NCT07778056	Neoadjuvant Chemoradiotherapy Versus Neoadjuvant Immunochemotherapy for Resectable Esophageal Cancer: A Target Trial Emulation Study	Henan Cancer Hospital	Observational	Not yet recruiting	Esophageal Squamous Cell Carcinoma (ESCC)	400		clinicaltrials.gov
August 18, 2026	NCT07769866	Retlirafusp Alfa Combined With Chemoradiotherapy in Unresectable ESCC	RenJi Hospital	Not applicable	Not yet recruiting	Esophageal Squamous Cell Cancer	68	China	clinicaltrials.gov
August 18, 2026	NCT07769658	Standardized MRI and Structured Reporting for Esophageal Squamous Cell Carcinoma	The First Affiliated Hospital of Zhengzhou University	Observational	Not yet recruiting	Esophageal Squamous Cell Carcinoma	500	China	clinicaltrials.gov
August 11, 2026	NCT07757906	Clinical Application of an AI-based Dissection Trajectory Prediction System (ADTPS) in Endoscopic Submucosal Dissection	Qilu Hospital of Shandong University	Not applicable	Active not recruiting	Esophageal Squamous Cell Carcinoma (ESCC), High-Grade Intraepithelial Neoplasia, AI-Based Dissection Trajectory...	220	China	clinicaltrials.gov
August 7, 2026	NCT07751055	Neoadjuvant Chemoradiotherapy Combined With CTLA-4 Monoclonal Antibody Plus PD-1 Monoclonal Antibody for Locally Advanced Esophageal Cancer	Sun Yat-sen University	Phase 2	Recruiting	Esophageal Squamous Cell Carcinoma (ESCC)	51	China	clinicaltrials.gov
August 4, 2026	NCT07745322	Spatial MSC Index for Predicting Anti-PD-1 Efficacy in Esophageal Cancer	Peking University Cancer Hospital & Institute	Observational	Active not recruiting	Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms	270	China	clinicaltrials.gov
July 29, 2026	NCT07733830	Comparing ICI Followed By CCRT And CCRT Followed By Immunotherapy In Unresectable LA-ESCC	Tianjin Medical University Cancer Institute and Hospital	Phase 2	Recruiting	Esophageal Cancer	120	China	clinicaltrials.gov
July 29, 2026	NCT07733180	A Study Investigating Alternate Schedules of Tislelizumab Plus Chemotherapy in Japanese Patients With First-line Advanced ESCC	BeOne Medicines	Phase 2	Recruiting	Advanced Esophageal Squamous Cell Carcinoma, Metastatic Esophageal Squamous Cell Carcinoma	30	Japan	clinicaltrials.gov
July 28, 2026	NCT07730021	A Study of ASP388B Given by Itself and With Standard Therapies in Participants With Solid Tumors	Astellas Pharma Global Development, Inc.	Phase 1/2	Recruiting	Locally Advanced or Metastatic Solid Tumors	392	Japan, United States	clinicaltrials.gov
July 22, 2026	NCT07721103	Early Response-guided Sequential Radiotherapy After Chemoimmunotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma	Tianjin Medical University Cancer Institute and Hospital	Phase 2	Not yet recruiting	Esophageal Squamous Cell Carcinoma (ESCC)	110	China	clinicaltrials.gov
July 20, 2026	NCT07714538	Breath Research Narrow Validation for Gastrointestinal Cancer Detection	Imperial College London	Observational	Recruiting	Oesophageal Squamous Cell Carcinoma, Oesophageal Adenocarcinoma, Gastric Adenocarcinoma, Pancreatic Ductal...	1,000	United Kingdom	clinicaltrials.gov
July 17, 2026	NCT07711470	Phase II Study of Induction Chemoimmunotherapy Followed by Radiotherapy and Organ Preservation in Resectable ESCC	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	Phase 2	Active not recruiting	Esophageal Squamous Cell Carcinoma (ESCC)	140	China	clinicaltrials.gov
July 16, 2026	NCT07709533	An Umbrella-designed Prospective Multicenter Randomized Open-label Superiority Trial Evaluating Multi-biomarker-guided Precision Therapy...	Sun Yat-sen University	Phase 2	Not yet recruiting	Valid MeSH Conditions	347	China	clinicaltrials.gov
July 15, 2026	NCT07705412	Postoperative Radiotherapy and Lymph Node Dissection After Neoadjuvant Immunochemotherapy for Esophageal Squamous Cell Carcinoma	Tongji Hospital	Observational	Completed	Esophageal Squamous Cell Carcinoma (ESCC)	465	China	clinicaltrials.gov
July 14, 2026	NCT07702253	O-GlcNAcylation Induced HMGB1 Signalling	Chinese University of Hong Kong	Observational	Active not recruiting	Esophageal Squamous Cell Carcinoma (ESCC)	120	Hong Kong	clinicaltrials.gov
July 14, 2026	NCT07701681	Sacituzumab Tirumotecan (Sac-TMT/SKB264) Plus Tagitanlimab (KL-A167) in Patients With Recurrent or Metastatic Esophageal Squamous Cell...	Sun Yat-sen University	Phase 2	Not yet recruiting	ESCC, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Esophageal Squamous Cell Carcinoma (ESCC)...	75	China	clinicaltrials.gov
July 14, 2026	NCT07700667	SKB500 Combinations in Patients With Esophageal Squamous Cell Carcinoma	Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.	Phase 2	Recruiting	Esophageal Squamous Cell Carcinoma	120	China	clinicaltrials.gov
July 13, 2026	NCT07699185	Neoadjuvant Cardonilizumab Combined With Neoadjuvant Chemoradiotherapy Can Resect Locally Advanced Esophageal Squamous Cell Carcinoma	Tongji Hospital	Phase 2	Recruiting	Esophageal Squamous Cell Carcinoma	336	China	clinicaltrials.gov
July 13, 2026	NCT07697898	TDLN-Guided Lymphadenectomy After Neoadjuvant Immunochemotherapy for ESCC	Tongji Hospital	Observational	Not yet recruiting	Esophageal Squamous Cell Carcinoma (ESCC)	400		clinicaltrials.gov
July 13, 2026	NCT07697859	PD-1 Inhibitors Combined With Local Therapy at Different Timings in Oligometastatic ESCC	Fudan University	Observational	Recruiting	Esophageal Squamous Cell Carcinoma (ESCC)	354	China	clinicaltrials.gov
July 10, 2026	NCT07697040	Becotatug Vedotin Plus Cisplatin and Radiotherapy in LA-ESCC	Hebei Medical University Fourth Hospital	Phase 1	Not yet recruiting	Esophageal Squamous Cell Carcinoma	12	China	clinicaltrials.gov
July 7, 2026	NCT07688291	A Phase II Study of PD-1/IL-2α-bias Bispecific Antibody Fusion Protein Monotherapy in Advanced Esophageal Squamous Cell Carcinoma After...	Beijing GoBroad Hospital	Phase 2	Not yet recruiting	Esophageal Squamous Carcinoma Cell	40	China	clinicaltrials.gov
July 7, 2026	NCT07686926	Becotatug Vedotin Plus Tislelizumab and Low-Dose Lenvatinib for Advanced Esophageal Squamous Cell Carcinoma, Phase II	Tianjin Medical University Cancer Institute and Hospital	Phase 2	Not yet recruiting	Esophageal Squamous Cell Carcinoma	36		clinicaltrials.gov
July 2, 2026	NCT07682376	Low-Dose Radiotherapy With Retlirafusp Alfa and Chemotherapy as Neoadjuvant Therapy for Resectable Locally Advanced Esophageal Squamous...	Harbin Medical University	Phase 2	Active not recruiting	Esophageal Squamous Cell Carcinoma (ESCC)	96	China	clinicaltrials.gov
July 1, 2026	NCT07678580	Neoadjuvant Short-Course Radiotherapy Plus Tislelizumab and Chemotherapy for Locally Advanced Resectable Esophageal Squamous Cell Carcinoma	Tang-Du Hospital	Phase 2	Not yet recruiting	Esophageal Squamous Cell Carcinoma (ESCC)	50	China	clinicaltrials.gov
June 17, 2026	NCT07653451	Precision Medicine for Immunotherapy-Resistant Advanced Esophageal Cancer	Peking University Cancer Hospital & Institute	Phase 2/3	Not yet recruiting	Esophageal Squamous Cell Carcinoma	90		clinicaltrials.gov
June 10, 2026	NCT07638436	Adebrelimab Combined With Neoadjuvant Chemotherapy in Borderline Resectable Locally Advanced Esophageal Squamous Cell Carcinoma	Sun Yat-sen University	Phase 2	Recruiting	Esophageal Squamous Cell Carcinoma (ESCC)	42	China	clinicaltrials.gov
June 5, 2026	NCT07629817	Surgery vs. Radical Chemoradiotherapy for Esophageal SCC After Neoadjuvant Immunochemotherapy	Henan Cancer Hospital	Phase 3	Recruiting	Esophageal Squamous Cell Carcinoma	1,044	China	clinicaltrials.gov
June 3, 2026	NCT07623642	A Phase II Study of GV20-0251 in Combination With Anti-PD-1 Monoclonal Antibodies in Patients With Unresectable, Locally Advanced, or...	GV20 Therapeutics	Phase 2	Not yet recruiting	Uterine Cervical Neoplasms, Triple Negative Breast Neoplasms, Prostatic Neoplasms, Squamous Cell Carcinoma of Head and...	227	China	clinicaltrials.gov
June 2, 2026	NCT07621601	A Study of HS-20093 in Patients With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC)	Hansoh BioMedical R&D Company	Phase 3	Not yet recruiting	Esophageal Squamous Cell Carcinoma (ESCC)	494		clinicaltrials.gov
June 1, 2026	NCT07618910	Retlirafusp Alfa Plus Chemotherapy as Neoadjuvant Therapy for Thoracic ESCC	Tang-Du Hospital	Phase 2	Not yet recruiting	Esophageal Squamous Cell Carcinoma	33	China	clinicaltrials.gov
May 26, 2026	NCT07605663	an AI-Driven Four-Tier Invasion Depth Classification for Early Esophageal Cancer	Fudan University	Observational	Active not recruiting	Esophageal Squamous Cell Carcinoma	890	China	clinicaltrials.gov
May 22, 2026	NCT07602842	A Study of IDP-001 in Advanced or Metastatic Solid Tumors	InduPro, Inc.	Phase 1/2	Recruiting	Advanced Solid Tumor, Metastatic Solid Tumor, Head and Neck Squamous Cell Carcinoma, Cutaneous Squamous Cell Carcinoma...	132	United States	clinicaltrials.gov
May 19, 2026	NCT07595770	Adebrelimab Combined With Neoadjuvant Chemoradiotherapy for Esophageal Squamous Cell Carcinoma	Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University	Phase 2	Recruiting	Esophageal Squamous Cell Carcinoma (ESCC)	37	China	clinicaltrials.gov
May 12, 2026	NCT07581236	The Efficacy of Inflatable Mediastinoscopic-assisted Transhiatal Laparoscopic Esophagectomy	Sun Yat-sen University	Not applicable	Completed	Esophageal Squamous Cell Carcinoma (ESCC)	35	China	clinicaltrials.gov
May 7, 2026	NCT07573397	A Prospective Study of Tumor-specific Tpex in Negative Lymph Nodes for Predicting Pathological Complete Response to Neoadjuvant PD 1...	Fudan University	Observational	Not yet recruiting	Esophageal Cancer	88		clinicaltrials.gov
May 5, 2026	NCT07567716	Infiltration Pattern of Locally Advanced ESCC	Shanghai Chest Hospital	Observational	Enrolling by invitation	Esophageal Squamous Cell Carcinoma (ESCC), Infiltration, Tumour	30	China	clinicaltrials.gov
April 30, 2026	NCT07559045	Induction Chemo-Immunotherapy + Radiotherapy vs Concurrent Chemoradiotherapy for Unresectable Locally Advanced Esophageal Squamous Cell...	Second Affiliated Hospital of Zunyi Medical University	Phase 2	Recruiting	Esophageal Squamous Cell Carcinoma (ESCC)	92	China	clinicaltrials.gov
April 28, 2026	NCT07554521	A Study to Evaluate Efficacy and Safety of Tislelizumab Plus Chemotherapy for Locally Advanced Unresectable or Metastatic Gastric or...	BeOne Medicines	Phase 2	Recruiting	Advanced Unresectable Gastric Adenocarcinoma, Esophageal Squamous Cell Carcinoma, Advanced Gastroesophageal...	30	United States	clinicaltrials.gov
April 28, 2026	NCT07554456	A Study of BL-B01D1 in Combination With Tislelizumab ±5-Fluorouracil Versus Platinum-Based Chemotherapy Plus Tislelizumab as First-line...	Sichuan Baili Pharmaceutical Co., Ltd.	Phase 2/3	Recruiting	Esophageal Squamous Cell Carcinoma	90	China	clinicaltrials.gov
April 16, 2026	NCT07533357	Tpex Subsets in Negative Tumor Draining Lymph Nodes for Predicting the Efficacy of PD 1 Inhibitors in Advanced or Recurrent Esophageal...	Fudan University	Observational	Not yet recruiting	Esophageal Cancer	158		clinicaltrials.gov
April 9, 2026	NCT07519486	Intensive Nutritional Support in Conversion Therapy for Locally Advanced Unresectable ESCC	Sichuan University	Phase 2	Recruiting	Esophageal Squamous Cell Carcinoma, Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma	118	China	clinicaltrials.gov
April 1, 2026	NCT07505186	Camrelizumab, Chemotherapy and Ivarmacitinib in Patients With Resectable Esophageal Squamous Cell Carcinoma	Second Affiliated Hospital, Zhejiang University, School of Medicine	Phase 2	Recruiting	Esophageal Squamous Cell Carcinoma, Neoadjuvant Therapy	45	China	clinicaltrials.gov
March 31, 2026	NCT07503808	A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types	IDEAYA Biosciences	Phase 1	Recruiting	Esophageal Squamous Cell Carcinoma, High Grade Serous Ovarian Cancer, Head and Neck Squamous Cell Carcinoma, Colorectal...	150	United States	clinicaltrials.gov
March 23, 2026	NCT07488624	Survival Prediction After Neoadjuvant Chemoimmunotherapy and Esophagectomy for Esophageal Squamous Cell Carcinoma	Sichuan University	Observational	Completed	Esophageal Squamous Cell Carcinoma	414	China	clinicaltrials.gov
March 19, 2026	NCT07482774	Tumor Microenvironment Changes After Neoadjuvant Chemo-Immunotherapy in Esophageal Squamous Cell Carcinoma	Nanjing Medical University	Observational	Not yet recruiting	Esophageal Squamous Cell Carcinoma	12		clinicaltrials.gov
March 18, 2026	NCT07481058	KC1036 in Combination With PD-1 Antibody and Platinum-based Chemotherapy for First-line Advanced Esophageal Cancer	Beijing Konruns Pharmaceutical Co., Ltd.	Phase 2	Recruiting	Esophageal Squamous Cell Carcinoma (ESCC)	60	China	clinicaltrials.gov
March 11, 2026	NCT07463573	QLC5508 vs. Chemotherapy in Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma	Qilu Pharmaceutical Co., Ltd.	Phase 3	Recruiting	Esophageal Squamous Cell Carcinoma (ESCC)	466	China	clinicaltrials.gov
March 9, 2026	NCT07457528	Efficacy and Safety of Neo-CRT Plus Serplulimab, Nimotuzumab in Patients With Locally Advanced Resectable ESCC	Tianjin Medical University Cancer Institute and Hospital	Phase 2	Recruiting	Resectable Esophageal Squamous Cell Carcinoma	46	China	clinicaltrials.gov
March 5, 2026	NCT07452601	Time-of-Day of Immunotherapy Infusion in Neoadjuvant Immunochemotherapy for Thoracic ESCC	Tang-Du Hospital	Phase 2	Recruiting	Esophageal Squamous Cell Carcinoma	90	China	clinicaltrials.gov
February 27, 2026	NCT07437898	Neoadjuvant Adebrelimab Plus Chemotherapy for Esophageal Cancer: A Clinical Study	The Affiliated Hospital of Putian University	Phase 2	Recruiting	Esophageal Squamous Cell Carcinoma	42	China	clinicaltrials.gov
February 12, 2026	NCT07405151	A Clinical Trial of Ifinatamab Deruxtecan in People With Advanced Esophageal Cancer (MK-3475-06F)	Merck Sharp & Dohme LLC	Phase 1/2	Recruiting	Oesophageal Squamous Cell Carcinoma	60	Brazil, Chile, China, Czechia, Japan, Norway, South Korea, Switzerland, Taiwan...	clinicaltrials.gov
February 11, 2026	NCT07403435	Short-course Radiotherapy Combined With Serplulimab and Chemotherapy as Neoadjuvant Treatment for Resectable ESCC	Union Hospital, Tongji Medical College, Huazhong University of Science and Technology	Phase 2	Not yet recruiting	Esophageal Squamous Cell Carcinoma (ESCC)	22	China	clinicaltrials.gov
February 11, 2026	NCT07403136	Becotatug Vedotin ± Anti-PD-1 in Pretreated Advanced ESCC	Fudan University	Phase 2	Recruiting	Esophageal Squamous Cell Carcinoma	104	China	clinicaltrials.gov
February 3, 2026	NCT07385001	A Prospective, Multicenter, Phase Ib/II Trial of Ivonescimab (AK112) Combined With Albumin-Paclitaxel and Cisplatin as Neoadjuvant Therapy...	Tang-Du Hospital	Phase 1/2	Recruiting	Esophageal Squamous Cell Carcinoma, Ivonescimab, Neoadjuvant	45	China	clinicaltrials.gov
January 29, 2026	NCT07376876	Indocyanine Green-guided Omental Shield Anastomosis for Cervical Esophagogastric Anastomosis in Minimally Invasive McKeown Esophagectomy	Daping Hospital and the Research Institute of Surgery of the Third Military Medical University	Phase 2	Not yet recruiting	Esophageal Squamous Cell Carcinoma (ESCC), Esophageal Cancer	73	China	clinicaltrials.gov
January 28, 2026	NCT07374003	Ipromlimab and Tuvonralimab Combined With Albumin-Bound Paclitaxel and Nedaplatin as Neoadjuvant Therapy for Locally Advanced Resectable...	Sun Yat-sen University	Phase 2	Active not recruiting	Locally Advanced, Resectable	62	China	clinicaltrials.gov
January 23, 2026	NCT07363629	Impact of Preserving Versus Ligating the Right Gastric Artery on Anastomotic Outcomes After McKeown Esophagectomy: A Randomized Controlled...	The First Hospital of Hebei Medical University	Not applicable	Completed	Esophageal Squamous Cell Carcinoma	120	China	clinicaltrials.gov
January 22, 2026	NCT07359417	MR-Guided Radiotherapy Dose Escalation Trial for Esophageal Squamous Cell Carcinoma	UMC Utrecht	Phase 1	Recruiting	Esophageal Squamous Cell Carcinoma (ESCC), Esophageal Cancer, Squamous Cell	30	Netherlands	clinicaltrials.gov
January 20, 2026	NCT07353541	Standardized Management of Esophageal Fistula in Esophageal Squamous Cell Carcinoma	Peking University Cancer Hospital & Institute	Observational	Not yet recruiting	Esophageal Squamous Cell Carcinoma (ESCC), Esophageal Fistula	32		clinicaltrials.gov
January 15, 2026	NCT07343869	Multicenter Prospective Cohort on Esophageal Endoscopic Submucosal Dissection	Société Française d'Endoscopie Digestive	Observational	Recruiting	Superficial Esophageal Cancer, Oesophageal Adenocarcinoma, Oesophageal Squamous Cell Carcinoma, Barretts Esophagus With...	750	France	clinicaltrials.gov
January 14, 2026	NCT07339488	Intestinal Low-Dose Radiotherapy Plus Immunochemotherapy for Conversion of Borderline Resectable/Unresectable Esophageal Squamous Cell...	Chuangzhen Chen	Phase 2	Recruiting	Borderline Resectable Carcinoma, Unresectable Cancer, Esophageal Squamous Cell Carcinoma (ESCC), Immune Checkpoint...	39	China	clinicaltrials.gov
January 5, 2026	NCT07317609	Neoadjuvant Immunotherapy Combined With Chemotherapy Sequenced With Endoscopic Resection for Esophageal Cancer (Endosurgery-02)	Shanghai Zhongshan Hospital	Phase 1	Recruiting	Esophageal Squamous Cell Carcinoma (ESCC)	60	China	clinicaltrials.gov
December 31, 2025	NCT07312578	Nimotuzumab,Camrelizumab, and Neoadjuvant Chemotherapy（nCT） in the Treatment of Esophageal Squamous Cell Carcinoma	Peking University	Phase 2	Enrolling by invitation	Esophageal Squamous Cell Carcinoma	48	China	clinicaltrials.gov
December 17, 2025	NCT07290010	The Efficacy and Safety of Iparomlimab and Tuvonralimab Injection Combined With Chemotherapy as the First-line Treatment for Esophageal...	Hebei Medical University Fourth Hospital	Phase 2	Recruiting	Esophageal Squamous Cell Carcinoma (ESCC)	25	China	clinicaltrials.gov
December 16, 2025	NCT07284186	First-in-Human Study of PLX-61639 in Locally Advanced or Metastatic Solid Tumors	Plexium, Inc.	Phase 1	Recruiting	Esophageal Squamous Cell Carcinoma, Gastric Adenocarcinoma, Gastric Squamous Cell Carcinoma, Gastroesophageal Junction...	155	United States	clinicaltrials.gov
December 11, 2025	NCT07277413	A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors	IDEAYA Biosciences	Phase 1	Recruiting	NSCLC Adenocarcinoma, Gastroesophageal Cancer (GC), Gastric Adenocarcinoma, Adenocarcinoma of Esophagus, Squamous Cell...	260	United States	clinicaltrials.gov
December 9, 2025	NCT07272291	A Phase II Study of Toripalimab Plus Chemotherapy and Low-Dose Radiotherapy for Neoadjuvant Therapy-Refractory Esophageal Squamous Cell...	Tianjin Medical University Cancer Institute and Hospital	Phase 2	Not yet recruiting	Esophageal Squamous Cell Carcinoma (ESCC)	48		clinicaltrials.gov
December 5, 2025	NCT07266493	Efficacy and Safety of Neoadjuvant Envafolimab Combined With Albumin-bound Paclitaxel and Carboplatin for Resectable Locally Advanced...	Shanghai Zhongshan Hospital	Phase 2	Recruiting	Esophageal Squamous Cell Carcinoma, Neoadjuvant Therapy	26	China	clinicaltrials.gov
December 5, 2025	NCT07266363	Integrated Cf-miRNA and Exosomal miRNA Signature for Early Detection of Esophageal Squamous Cell Carcinoma	City of Hope Medical Center	Observational	Recruiting	ESCC	600	United States	clinicaltrials.gov
November 26, 2025	NCT07251062	A Study of SYS6010, Enlonstobart, and Chemotherapy for First-Line Treatment of Esophageal Squamous Cell Carcinoma.	CSPC Megalith Biopharmaceutical Co.,Ltd.	Phase 2/3	Not yet recruiting	Esophageal Squamous Cell Carcinoma	737		clinicaltrials.gov
November 24, 2025	NCT07246330	Stratified Treatment in Unresectable Locally Advanced ESCC Without Progression After Chemoimmunotherapy Induction Plus CCRT: Toripalimab...	Tianjin Medical University Cancer Institute and Hospital	Phase 3	Recruiting	Esophageal Squamous Cell Carcinoma (ESCC)	340	China	clinicaltrials.gov
November 24, 2025	NCT07244978	Neoadjuvant Ivonescimab（AK112） Combined With Chemotherapy in Patients With Resectable Esophageal Squamous Cell Carcinoma	Second Affiliated Hospital, Zhejiang University, School of Medicine	Phase 2	Recruiting	Esophageal Squamous Cell Carcinoma, Neoadjuvant Therapy	49	China	clinicaltrials.gov
November 19, 2025	NCT07236320	Neoadjuvant Immunochemotherapy vs Chemoradiotherapy in ESCC	Yongtao Han	Not applicable	Completed	Esophageal Squamous Cell Carcinoma (ESCC)	200	China	clinicaltrials.gov
November 14, 2025	NCT07229313	A Study of KIVU-107 in Participants With Locally Advanced or Metastatic Solid Tumors	Kivu Bioscience Inc.	Phase 1	Recruiting	Advance Solid Tumors	76	Australia, United States	clinicaltrials.gov
November 5, 2025	NCT07224750	A Noninvasive and Screening miRNA Signature for Gastrointestinal Cancer	City of Hope Medical Center	Observational	Recruiting	Hepatocellular Carcinoma (HCC), Cholangiocarcinoma, Pancreatic Ductal Adenocarcinoma (PDAC), Esophageal Squamous Cell...	1,000	United States	clinicaltrials.gov
October 20, 2025	NCT07218003	A Phase 1/1b of RNDO-564 Single Agent or in Combination With Pembrolizumab in Bladder Cancer and Other Solid Tumors Associated With Nectin-4	Rondo Therapeutics	Phase 1	Enrolling by invitation	Non Small Cell Lung Cancer, Cervical Cancer, Head and Neck Squamous Cell Cancer, Triple Negative Breast Cancer (TNBC)...	149	United States	clinicaltrials.gov
October 15, 2025	NCT07217171	A Study Evaluating the Safety, Efficacy, and Pharmacokinetics (PK) of EVOLVE104 in Participants With Advanced Urothelial and Squamous Cell...	EvolveImmune United, Inc	Phase 1	Recruiting	Bladder Cancer, Squamous Cell Carcinoma of the Lung, Esophageal Squamous Cell Carcinoma, Tongue Squamous Cell...	160	United States	clinicaltrials.gov
October 3, 2025	NCT07205731	Phase II Study Evaluating Safety and Efficacy of Tislelizumab for Elderly Patients Unfit for Chemotherapy, With Advanced Esophageal...	University Hospital, Clermont-Ferrand	Phase 2	Recruiting	Esophageal Squamous Cell Carcinoma (ESCC)	95	France	clinicaltrials.gov
October 2, 2025	NCT07203898	A Study of IPM514 in Patients With Esophageal Squamous Cell Carcinoma.	Beijing Immupeutics Medicine Technology Limited	Phase 1	Not yet recruiting	Esophageal Squamous Cell Carcinoma	36		clinicaltrials.gov
October 1, 2025	NCT07201571	A Retrospective Cohort Study of Patients Who Underwent Curative-intent Esophagectomy for ESCC at a Tertiary Referral Center in South Korea	Samsung Medical Center	Observational	Completed	Oesophageal Squamous Cell Carcinoma	3,131		clinicaltrials.gov
September 24, 2025	NCT07189871	177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors	Radiopharm Theranostics, Ltd	Phase 1/2	Recruiting	Castration-Resistant Prostate Cancer (CRPC), Colorectal Cancer, NSCLC (Non-small Cell Lung Cancer), Ovarian Cancer...	61	United States	clinicaltrials.gov
September 23, 2025	NCT07188103	Ivonescimab Plus Short-Course Hypofractionated Radiotherapy as Second-Line Therapy for Esophageal Squamous Cell Carcinoma	Anhui Provincial Hospital	Phase 2	Recruiting	Esophageal Squamous Cell Carcinoma	37	China	clinicaltrials.gov
September 18, 2025	NCT07181850	Predicting Pathological Complete Response in Esophageal Squamous Cell Carcinoma Using a Multimodal Model Integrating Clinical, Radiomics...	Nanjing Medical University	Observational	Completed	Esophageal Squamous Cell Carcinoma, Pathological Complete Response	363	China	clinicaltrials.gov
September 17, 2025	NCT07177794	Consolidation of Toripalimab and Capecitabine After Chemoradiotherapy in ESCC	Sun Yat-sen University	Phase 3	Recruiting	Esophageal Cancer, Chemoradiotherapy	242	China	clinicaltrials.gov
September 4, 2025	NCT07154108	Endostatin Adenovirus With Checkpoint Inhibitor in Advanced Head and Neck or Esophageal Cancer	Sichuan University	Phase 1	Not yet recruiting	Esophageal Cancer, Head and Neck Cancer (H&Amp;Amp;Amp;N)	40	China	clinicaltrials.gov
September 3, 2025	NCT07152678	Brachytherapy With Radiotherapy and Immunotherapy: Guided HDR Trial in Esophageal Squamous Cell Carcinoma	National Taiwan University Hospital	Phase 2	Recruiting	Esophageal Cancer, Esophageal Squamous Cell Carcinoma	60	Taiwan	clinicaltrials.gov
September 3, 2025	NCT07152535	Multi-omics Monitoring of Dynamic Evolution in Esophageal Squamous Cell Carcinoma: PKU-ESCC-Monitor	Peking University Cancer Hospital & Institute	Observational	Not yet recruiting	Esophageal Squamous Cell Carcinoma (ESCC)	255		clinicaltrials.gov

Sponsors posting most

Sponsor	New trials	Latest
Sun Yat-sen University	10	August 7, 2026
Cancer Institute and Hospital, Chinese Academy of Medical Sciences	6	October 19, 2026
Peking University Cancer Hospital & Institute	6	September 16, 2026
Tianjin Medical University Cancer Institute and Hospital	6	July 29, 2026
Fudan University	6	July 13, 2026
Hebei Medical University Fourth Hospital	5	September 16, 2026
Tang-Du Hospital	5	July 1, 2026
Sichuan University	5	April 9, 2026
Shanghai Chest Hospital	4	September 21, 2026
The First Affiliated Hospital of Zhengzhou University	4	August 18, 2026
Tongji Hospital	4	July 15, 2026
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University	3	October 29, 2026
Peking University	3	December 31, 2025
CSPC Megalith Biopharmaceutical Co.,Ltd.	2	November 9, 2026
Vanderbilt-Ingram Cancer Center	2	September 23, 2026
Henan Cancer Hospital	2	August 21, 2026
RenJi Hospital	2	August 18, 2026
BeOne Medicines	2	July 29, 2026
Second Affiliated Hospital, Zhejiang University, School of Medicine	2	April 1, 2026
IDEAYA Biosciences	2	March 31, 2026

By phase

Phase	New trials	Latest
Phase 2	59	September 23, 2026
Observational	33	October 29, 2026
Phase 1	14	July 10, 2026
Phase 1/2	12	November 2, 2026
Phase 3	9	November 9, 2026
Not applicable	9	August 18, 2026
Phase 2/3	5	June 17, 2026
Early phase 1	2	February 14, 2025

By country

Country	New trials	Latest
China	92	October 19, 2026
United States	22	November 2, 2026
France	6	January 15, 2026
Taiwan	5	February 12, 2026
Japan	4	July 29, 2026
South Korea	4	February 12, 2026
United Kingdom	3	July 20, 2026
Spain	3	August 7, 2025
Hong Kong	2	July 14, 2026
Brazil	2	February 12, 2026
Chile	2	February 12, 2026
Czechia	2	February 12, 2026
Norway	2	February 12, 2026
Switzerland	2	February 12, 2026
Thailand	2	February 12, 2026
Puerto Rico	2	August 7, 2025
Italy	2	January 17, 2025
Singapore	2	January 17, 2025
Netherlands	1	January 22, 2026
Australia	1	November 14, 2025
Ireland	1	August 7, 2025
Portugal	1	August 7, 2025
Canada	1	July 29, 2025
Germany	1	January 17, 2025
Turkey (Türkiye)	1	January 17, 2025

Where the register publishes

U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Condition groups are the MeSH terms ClinicalTrials.gov assigns to each study's conditions; a study with several is in several groups. Sponsor class is the register's class of the lead sponsor. The central contact is in the full list only as the record prints it. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.

$10 of credit on sign-up, no card.

Get this list free